Related Experiment Video
Updated: Aug 16, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
Practical considerations in the treatment of ventricular arrhythmias with mexiletine
Abstract:
Mexiletine can be administered by intravenous, intramuscular, or oral route. However, the intramuscular route is seldom used because it offers no advantage over the other routes. Loading doses of about 400 mg may result in unacceptable side effects and are unnecessary for management of chronic ventricular arrhythmias. Therapeutic efficacy as well as side effects increase in proportion to increasing blood levels. At plasma levels of 2.0 mg/L, side effects are encountered in a significant number of patients. Because of its lack of serious toxicity even in patients with various systemic illnesses and its long elimination half-life, mexiletine should be considered as a first-line drug for treatment of ventricular arrhythmias.
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias VI: Management of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

